Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Insys Therapeutics Inc. (NASDAQ: INSY).

Full DD Report for INSY

You must become a subscriber to view this report.


Recent News from (NASDAQ: INSY)

Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
Maryland AG charges Insys Therapeutics with violating Consumer Protection Act; shares down 7%
The Consumer Protection Division of the Office of the Attorney General for the state of Maryland has charged INSYS Therapeutics ( INSY -6.8% ) with multiple violations of the Consumer Protection Act related to its marketing practices for opioid pain med Subsys (fentanyl). More news on:...
Source: SeekingAlpha
Date: September, 06 2018 12:31
Cannabis and Biotech Firms Set to Explode
HENDERSON,NV / ACCESSWIRE / September 4, 2018 / We have discovered an incredibly unique stem cell firm, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the street. As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lum...
Source: ACCESSWIRE IA
Date: September, 04 2018 10:05
INSYS Therapeutics and UC San Diego's Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis
PHOENIX, Sept. 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its clinical development collaboration with the Center for Medicinal ...
Source: GlobeNewswire
Date: September, 04 2018 06:00
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516...
Source: SeekingAlpha
Date: September, 01 2018 05:42
Midday Gainers / Losers (08/31/2018)
Gainers:  AOBC +37% . PDEX +23% . TLYS +19% . INNT +19% . GGAL +19% . BMA +19% . TPIV +18% . SUPV +17% . EDN +16% . LULU +16% . More news on: American Outdoor Brands Corporation, Pro-Dex, Inc., Tilly's, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 31 2018 12:42
Today's Research Reports on Stocks to Watch: INSYS Therapeutics and REGENXBIO
NEW YORK, NY / ACCESSWIRE / August 31, 2018 / Both INSYS Therapeutics and REGENXBIO were soaring in Thursday’s session on positive developments. INSYS was given fast track designation from the FDA for its epinephrine nasal spray as an investigational treatment for anaphylaxis. REGENX...
Source: ACCESSWIRE IA
Date: August, 31 2018 08:00
5 of Today's Biggest Marijuana Stock Gainers - Thursday, August 30th
Out of over 200+ marijuana stocks , here are 5 of the biggest marijuana stock winners in trading on Thursday, August 30th including CV Sciences, Inc. (OTC:CVSI) and more... CannTrust Holdings Inc. (TSX:TRST) (OTC:CNTTF) Shares of CannTrust Holdings Inc. rose 6.27% on higher than averag...
Source: Daily Marijuana Observer
Date: August, 30 2018 16:59
Clinical Stage Marijuana Focused Biotech Stocks Trend Higher In August
CORAL GABLES, FL / ACCESSWIRE / August 30, 2018 / Typically the stock market slows down toward the end of summer but this year that has not been the case. The markets are hitting all time highs and one of the top sectors leading the charge: biotechnology. Big pharma is weighing in on clinica...
Source: ACCESSWIRE IA
Date: August, 30 2018 13:30
Midday Gainers / Losers (08/30/2018)
Gainers:   REIS +32% . SIG +28% . KTWO +26% . SHOS +24% . INSY +23% . CVM +19% . DXLG +18% . PARR +18% . ALRN +18% . GALT +16% . More news on: Reis, Inc, Signet Jewelers Limited, K2M Group Holdings, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 30 2018 12:36

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-087.938.278.607.93586,002
2018-05-177.137.347.42947.07492,162
2017-11-275.195.335.335.04772,415
2017-11-245.285.055.295.05514,915
2017-11-225.275.205.305.16395,784

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18140,649447,41631.4358Cover
2018-12-17140,817242,55058.0569Short
2018-12-1457,420216,05826.5762Cover
2018-12-1370,631213,07333.1487Cover
2018-12-12109,735622,18317.6371Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INSY.


About Insys Therapeutics Inc. (NASDAQ: INSY)

Logo for Insys Therapeutics Inc. (NASDAQ: INSY)

Not available

 

Contact Information

 

 

Current Management

  • Michael Babich / President, COO
  • Matthew Napoletano / VP, Mkt.
  • Martin K. McCarthy / Controller

Current Share Structure

  • Market Cap: $478,222,430 - 05/11/2018
  • Issue and Outstanding: 69,915,560 - 06/08/2015

 


Recent Filings from (NASDAQ: INSY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018

 

 


Daily Technical Chart for (NASDAQ: INSY)

Daily Technical Chart for (NASDAQ: INSY)


Stay tuned for daily updates and more on (NASDAQ: INSY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INSY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INSY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INSY and does not buy, sell, or trade any shares of INSY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/